Friday January 19th 2018

Gene Expression Analysis Shows Varying Reactions to Teva’s COPAXONE (GA) vs a Generic

Teva Pharmaceuticals announced the release of data demonstrating substantial differences in biological and immunological effects concerning its product Copaxone (glatiramer acetate, GA) and a generic GA commercialized in India. Copaxone is indicated for decreasing relapse frequency in relapsing remitting multiple sclerosis (MS). Multiple sclerosis affects more than 2 million people all over the world. The published data holds possibilities for clinical ramifications. (Source: Pharmaceutical Online News)

Continue reading here:  

Gene Expression Analysis Shows Varying Reactions to Teva’s COPAXONE (GA) vs a Generic

Leave a Comment

More from category

Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases
Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases

An international team of researchers led by prof. Savvas Savvides has unraveled a crucial aspect of the molecular basis [Read More]

Kessler Foundation wins $735,000 grant for training rehabilitation researchers
Kessler Foundation wins $735,000 grant for training rehabilitation researchers

Guang Yue, PhD, director of Human Performance and Engineering Research at Kessler Foundation, has been awarded a [Read More]

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]